APPARATUS AND METHODS FOR NONINVASIVE MONITORING OF CANCEROUS CELLS

• US 20140200481A1
• Filed: 01/14/2014
• Published: 07/17/2014
• Est. Priority Date: 02/16/2011
• Status: Active Grant

• Current Assignee: Sequana Medical AG (Sequana Medical NV)
• Original Assignee: Sequana Medical AG (Sequana Medical NV)
• Inventors: Johnson, Noel L., Whittaker, Steve
• Granted Patent: US 9,675,327 B2
• Time in Patent Office: Days
• US Class Current: 600/561
• CPC Class Codes: A61B 10/007 for taking urine samples measuring urological functions A61B5/20; genital receptacles A61F5/451; urinals for bed-ridden persons A61G9/006
• CPC Class Codes: A61M 2205/3507 with implanted devices, e.g. external control
• CPC Class Codes: A61M 2205/3569 sublocal, e.g. between console and disposable
• CPC Class Codes: A61M 2205/8243 by induction
• CPC Class Codes: A61M 5/14236 Screw, impeller or centrifugal type pumps
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: G01N 33/493 urine

Abstract

A system for noninvasively monitoring cancerous cells within bodily fluid accumulated due to ascites, pleural effusion or pericardial effusion is provided including an implantable pump having control circuitry; a charging and communication system configured to periodically charge and communicate with the implantable pump to retrieve performance data; and monitoring and control software, suitable for use with conventional personal computers, for configuring and controlling operation of the implantable pump and charging and communication system. The implantable pump is configured to move fluid containing cancerous cells from a body cavity to the bladder such that the fluid may be excreted during urination, collected and analyzed with an analysis station to assess progress of the cancer or efficacy of a cancer treatment program.

Claims

1. A system for noninvasive monitoring of cancerous cells of a patient having cancer, comprising:

an inflow catheter having an inlet end and an outlet end, the inlet end adapted to be positioned within a body cavity having an accumulation of fluid comprising cancerous cells;

an outflow catheter having an inlet end and an outlet end adapted to be positioned in a bladder;

an implantable pump having a first controller, an inlet port coupled to the outlet end of the inflow catheter and an outlet port coupled to the inlet end of the outflow catheter, the first controller is programmed to selectively activate the implantable pump to move the fluid comprising cancerous cells from the inlet end of the inflow catheter to the bladder during predetermined time periods; and

an analysis station configured to analyze fluid including cancerous cells excreted from the bladder during urination to determine a parameter indicative of the progress of the cancer or an efficacy of a program to treat to the cancer.

2. The system of claim 1, wherein the inlet end of the inflow catheter is adapted to be positioned in a peritoneal cavity, a pleural cavity, or a pericardial cavity.

3. The system of claim 1, wherein the implantable device further comprises a first pressure sensor configured to measure inflow catheter pressure and a second pressure sensor configured to measure outflow catheter pressure.

4. The system of claim 1, wherein the implantable device further comprises at least one valve that prevents reverse flow from the outflow catheter to the inflow catheter.

5. The system of claim 1 wherein the implantable device further comprises a battery, a first transceiver, and a first inductive charging circuit coupled to the first controller and the system further comprises:

a charging and communication system comprising a second controller coupled to a second transceiver and a second inductive charging circuit, the charging and communication system configured to wirelessly communicate with the implantable device via the first and second transceivers, and to wirelessly transfer energy from the second inductive circuit to the first inductive circuit to charge the first battery.

6. The system of claim 5, wherein the charging and communication system further comprises:

a handpiece housing the second controller, the second transceiver, the second inductive charging circuit and a second battery; and

a base containing circuitry for charging the second battery.

7. The system of claim 5, further comprising:

monitoring and control software configured to run on a computer, the monitoring and control software configured to communicate operational parameters to the implantable device via the charging and communication system to control operation of the pump.

8. The system of claim 7, wherein the first controller is programmed to automatically activate the pump to move fluid during predetermined time periods and in predetermined volumes responsive to operational parameters communicated by the monitoring and control software.

9. A system for noninvasive monitoring of cancerous cells comprising:

a fluid management system comprising;

an implantable pump having a first controller;

an inflow catheter having an inlet end adapted to be positioned within a body cavity and an outlet end configured to be coupled to the implantable pump, the body cavity having an accumulation of fluid comprising cancerous cells; and

an outflow catheter having an inlet end configured to be coupled to the implantable pump and an outlet end adapted to be positioned in a bladder,

wherein the first controller is programmed to selectively activate the implantable pump to move the fluid comprising cancerous cells from the inlet end of the inflow catheter to the bladder; and

an analysis station configured to analyze the cancerous cells.

10. The system of claim 9, wherein the analysis station is located remotely from the fluid management system.

11. The system of claim 9, wherein the inlet end of the inflow catheter is adapted to be positioned in a peritoneal cavity, a pleural cavity, or a pericardial cavity.

12. The system of claim 9, wherein the implantable device further comprises a first pressure sensor configured to measure inflow catheter pressure and a second pressure sensor configured to measure outflow catheter pressure.

13. The system of claim 9, wherein the implantable device further comprises at least one valve that prevents reverse flow from the outflow catheter to the inflow catheter.

14. The system of claim 9 wherein the implantable device further comprises a battery, a first transceiver, and a first inductive charging circuit coupled to the first controller and the fluid management system further comprises:

a charging and communication system comprising a second controller coupled to a second transceiver and a second inductive charging circuit, the charging and communication system configured to wirelessly communicate with the implantable device via the first and second transceivers, and to wirelessly transfer energy from the second inductive circuit to the first inductive circuit to charge the first battery.

15. The system of claim 14, wherein the charging and communication system further comprises:

a handpiece housing the second controller, the second transceiver, the second inductive charging circuit and a second battery; and

a base containing circuitry for charging the second battery.

16. The system of claim 14, further comprising:

monitoring and control software configured to run on a computer, the monitoring and control software configured to communicate operational parameters to the implantable device via the charging and communication system to control operation of the pump.

17. The system of claim 16, wherein the first controller is programmed to automatically activate pump to move fluid during predetermined time periods and in predetermined volumes responsive to operational parameters communicated by the monitoring and control software.

18. A method for noninvasive monitoring of cancerous cells in a patient with cancer, the method comprising:

pumping, via an implantable pump, bodily fluid comprising cancerous cells from a body cavity having an accumulation of the bodily fluid to the bladder for excretion;

collecting fluid excreted from the bladder during urination; and

analyzing cancerous cells contained with the fluid to determine a parameter indicative of progress of the cancer or efficacy of a cancer treatment program.

19. The method of claim 18, further comprising analyzing the cancerous cells to assess progress of a cancer treatment.

20. The method of claim 18, wherein pumping the bodily fluid from a the body cavity comprises pumping bodily fluid from a peritoneal cavity, a pleural cavity or a pericardial cavity.